CD274 and neoplasm: In this regard, increased PD-L1 expression (as measured by immunohistochemistry [IHC]) on the surface of tumor cells and/or immune cells, despite representing today the only form of approved companion diagnostics for immunotherapies targeting the PD-1 axis, has been shown to be only inconsistently associated with these agents’ clinical benefit [1].